2023 World Conference on Lung Cancer (Posters)-EP07.04. Current Biomarker Testing Practices for Early Stage Non-small Cell Lung Cancer (NSCLC) In Community and Academic Centers in the US

EP07.04. Current Biomarker Testing Practices for Early Stage Non-small Cell Lung Cancer (NSCLC) In Community and Academic Centers in the US - PDF(Abstract)

Back to course

Pdf Summary

This presentation focused on the current biomarker testing practices for early-stage Non-small Cell Lung Cancer (NSCLC) in community and academic centers in the US. The study aimed to understand the institutional practices around biomarker testing in surgically resected NSCLC patients. A survey was conducted in 2022 by the Association of Community Cancer Centers (ACCC) among individuals who provide care for NSCLC patients.<br /><br />The survey had a total of 124 respondents from 33 states in the US. The respondents worked in different types of institutions, including community cancer programs, academic/NCI designated cancer programs, and private practice. The survey evaluated issues related to the process of care for biomarker testing and biomarker-driven therapy.<br /><br />The results indicated that 66% of institutions had biomarker protocols for patients with resected NSCLC, while 21% did not, and 12% were unsure. When ordering tissue-based testing, 32% used next-generation sequencing (NGS), 44% used multiplex panel testing, 27% ordered EGFRm as a single test, and 11% were unsure. In terms of liquid biopsy, 14% ordered it for all resected NSCLC patients, 9% never ordered it, and 33% only ordered it when tissue testing was not performed.<br /><br />The survey also examined who typically ordered biomarker testing, with medical oncologists being the most common at 76%, followed by surgeons (29%), pathologists (28%), pulmonologists (17%), and advanced practice providers (10%). Multidisciplinary tumor boards were used by 31% for general cancer cases, 50% for thoracic specific cases, and 14% for dedicated molecular tumor boards.<br /><br />The use of biomarker testing protocols for resected NSCLC was more common when any multidisciplinary tumor board was used. However, the processes for biomarker testing and multidisciplinary decision making varied across institutions, indicating a need for quality improvement projects to increase standardization.<br /><br />In summary, the study found that there are different practices for biomarker testing in early-stage NSCLC among institutions in the US. This presents an opportunity for enhancing standardization to improve patient outcomes.

Asset Subtitle

Matthew Smeltzer

Meta Tag

Speaker Matthew Smeltzer

Topic Early-Stage NSCLC: Progress in Pathology

Keywords

biomarker testing

Non-small Cell Lung Cancer

NSCLC

institutional practices

survey

tissue-based testing

next-generation sequencing

liquid biopsy

multidisciplinary tumor boards

standardization